title: Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions.
abstract: Chronic myelogenous leukemia (CML) is a rare disease in children. There is little evidence of biological differences between CML in children and adults, although host factors are different. Children develop distinct morbidities related to the off-target effects of tyrosine kinase inhibitors. The goal of treatment in children should be cure rather than suppression of disease, which can be the treatment goal for many older adults. This article reviews data from the literature on the treatment of CML, discusses the issues that are unique to CML in children, and recommends management that takes these issues into consideration.
authors.affiliation: Division of Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 East Chicago Avenue, Box #30, Chicago, IL 60611, USA; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: nhijiya@luriechildrens.org.
authors.forename: Nobuko
authors.initials: N
authors.lastname: Hijiya
authors.affiliation: Centre d'Investigation Clinique 1402, Institut National de la Santé et de la Recherche Médicale (INSERM), University Hospital of Poitiers, 2 rue de la Milétrie, 86000 Poitiers, France.
authors.forename: Frederic
authors.initials: F
authors.lastname: Millot
authors.affiliation: Department of Pediatrics, University Hospital "Carl Gustav Carus", Fetscherstrasse 74, D-01307 Dresden, Germany.
authors.forename: Meinolf
authors.initials: M
authors.lastname: Suttorp
mesh_terms: D000328:Adult; D002648:Child; D003937:Diagnosis, Differential; D017408:Guidelines as Topic; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000628:therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use
chemical_list: D047428:Protein Kinase Inhibitors
keywords: BCR-ABL1; Chronic myeloid leukemia; Hematopoietic stem cell transplant; Tyrosine kinase inhibitor